Abbott Vascular announced today that the clinical trial has begun for its Absorb bioresorbable vascular scaffold (BVS). The Absorb BVS is made of polylactide, a naturally dissolvable material commonly used in medical implants such as dissolving sutures. Absorb works by opening a clogged vessel and restoring blood flow to the heart similar to a drug-eluting metal stent, the current standard of care. Absorb then dissolves into the blood vessel, which could allow for more natural function and movement of the vessel because it is free of a permanent metallic implant. The trial, called ABSORB III, will evaluate results in patients with coronary artery disease.
“The data collected on Absorb from the ABSORB III trial could have the potential to drive significant changes in how cardiologists treat patients with coronary artery disease,” said Stephen Ellis, MD, section head of interventional cardiology at the Cleveland Clinic and co-primary investigator of the ABSORB III trial in a press release.
Read more and share your thoughts at “Abbott Initiates Clinical Trial of Absorb in the United States.”